Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J · Journal of the National Comprehensive Cancer Network : JNCCN
Sarcoma subtypes
Abstract
Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Guidelines for Soft Tissue Sarcoma (available at NCCN.org) provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as intra-abdominal/retroperitoneal STS, gastrointestinal stromal tumor, desmoid tumors, and rhabdomyosarcoma. This manuscript discusses guiding principles for the diagnosis and staging of STS and evidence for treatment modalities that include surgery, radiation, chemoradiation, chemotherapy, and targeted therapy.
Shown exactly as published on PubMed. Your oncologist is the right person to judge whether these findings apply to your situation.
Publication type
Source: PubMed, PMID 27283169. Always confirm details with the original publication or your oncologist.